Association of chemokine receptor 5 (CCR5) Δ32 mutation with Behçet's disease is dependent on gender in Iranian patients

Clinical and Experimental Rheumatology

Volumn 24, Issue 5 SUPPL. 42, 2006, Pages

  Mojtahedi, Zahra ^a,b   Ahmadi, Shahram Baharvand ^b   Razmkhah, Mahboobeh ^b   Azad, Tahereh Khalili ^b   Rajaee, Akbar ^b   Ghaderi, Abbas ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Beh et's disease; CCR5; Polymorphism

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 DELTA 32; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BASE PAIRING; BEHCET DISEASE; CELL SURFACE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; ENVIRONMENTAL FACTOR; FEMALE; FISHER EXACT TEST; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; BEHCET SYNDROME; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; MALE; MIDDLE AGED; MUTATION; OPEN READING FRAMES; RECEPTORS, CCR5; RISK FACTORS; SEX FACTORS;

EID: 33750716062     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BEHÇET H: Dermatol Wochenschr 1937; 105: 1152-7.
2. GÜL A: Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2000; 19: S6-12.
3. GUL A: Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005; 4: 81-3.
4. SUZUKI KUROKAWA M, SUZUKI N: Behçet's disease. Clin Exp Med 2004; 3: 10-20.
5. SHAHRAM F, DAVATCHI F, NADJI A et al.: Recent epidemiologic data on Behçet's disease in Iran. The 2001 Survey. Adv Exp Med Biol 2003; 528: 31-6.
6. MIZUKI N, YABUKI K, OTA M et al.: Analysis of microsatellite polymorphism around the HLA-B locus in Iranian patients with Behçet's disease. Tissue antigens 2002; 60: 396-9.
7. CHEN Y, VAUGHAN RW, KONDEATIS E et al.: Chemokine gene polymorphisms associate with gender in pateints with uveitis. Tissue antigens 2004; 63: 41-45.
8. RIBEIRO S, HORUK R: The clinical potential of chemokine receptor antagonists. Pharmacol Ther 2005; 107: 44-58.
9. MUELLER A, STANGE PG: The chemokine receptor, CCR5. Int J Biochem Cell Biol 2004; 36: 35-8.
10. HOUMAN H, HAMZAOUI A, GHORBAL IM, KHANFIR M, FEKI M, HAMZAOUI K: Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun 2004; 23: 267-73.
11. PULKKINEN K, LUOMALA M, KUUSISTO H et al.: Increase in CCR5 Delta32/ Delta32 genotype in multiple sclerosis. Acta Neurol Scand 2004; 109: 342-7.
12. SORENSEN LN, PALUDAN SR: Blocking CC chemokine receptor (CCR) I and CCR5 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response. Scand J Immunol 2004; 59: 321-33.
13. NANSEN A, CHRISTENSEN JP, ANDREASEN SO, BARTHOLDY C, CHRISTENSEN JE, THAMSEN AR: The role of CC chemokine receptor 5 in antiviral immunity. Blood 2002; 99: 1237-45.
14. ALGOOD HM, FLYNN JL: CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. J Immunol 2004; 173: 3287-96.
15. MORENO C, GUSTOT T, NICAISE C et al.: CCR5 deficiency exacerbates T cell-mediated hepatitis in mice. Hepatology 2005; 42: 854-62.
16. WOITAS RP, AHLENSTIEL G, IWAN A et al.: Frequency of the HIV protective CC chemokine receptor 5- Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology 2002; 122: 1721-8.
17. International Study Group for Behçet's disease: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080.
18. MILLER SA, DYKES DD, POLESKY HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1998; 16: 1215.
19. GHARAGOZLOU M, DOROUDCHI M, FARJADIAN SH, PEZESHKI AM, GHADERI A: The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. Immunol Lett 2005; 96: 277-81.
20. YANG X, AHMAD T, GOGUS F et al.: Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behcet's disease. Eur J Immunogenet 2004; 31: 11-4.
21. SULIGOI B, TORRI A, TANZI E, PALU G: The Italian Herpes Management Forum. Seroprevalence and seroincidence of herpes simplex virus type 1 and herpes simplex virus type 2 infections in a cohorot of adolescents in Italy. Sex Transm Dis 2004; 31: 608-10.
22. BURGOS JS, RAMIREZ C, SASTRE I, ALFARO JM, VALDIVIESO F: Herpes simplex virus type 1 infection via the bloodstream with apolipoprotein E dependence in the gonads is influenced by gender. J Virol 2005; 79: 1605-12.
23. BARNA M, KOMATSU T, BI Z, REISS CS: Sex differences in susceptibility to viral infection of the central nervous system. J Neuroimmunol 1996; 67: 31-9.
24. BAO L, ZHU Y, ZHU J, LINDGREN JU: Decreased IgG production but increased MIP-1beta expression in collagen-induced arthritis in C-C chemokine receptor 5-deficient mice. Cytokine 2005; 31: 64-71.
25. TAKEUCHI A, USUI Y, TAKEUCHI M et al.: CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response. Invest Ophthalmol Vis Sci 2005; 46: 3753-60.
26. WYSOCKI CA, JANG Q, PANOSKALTSIS-MORTARI A et al.: Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005; 106: 3300-7.